- Wang YK, Wang YW, Lu CL, Huang YH, Hou MC, Chang YL, Lee WP*, Lan KH. Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. Scientific Report, 2022 Jun 15;12(1):9942
- Lee WP*. Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors. J Chin Med Assoc, 2022 Sep 1;85(9):915-921.
- Wang YW, Lee WP(co-first author), Huang YH, Hou MC, Lan KH. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):984-995.
- Wang YK, Lee WP (co-first author), Wang YW, Huang YH, Hou MC, Chang YL, Lan KH. Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir. J Chin Med Assoc. 2020, 83: 1071-1078
- Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH. Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus. J Chin Med Assoc. 2019;82:368-374.
- Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus. Am J Chin Med 2018;46:835-852.
- Lan KH, Lee WP, Wang YS, Liao SX, Lan KH. Helicobacter pylori CagA protein activates Akt and attenuates chemotherapeutics-induced apoptosis in gastric cancer cells. Oncotarget. 2017;8:113460-113471.
- *Lee WP, Lan KH, Li CP, Chao Y, Hou MC, Lin HC, Lee SD. The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine. BBA-Mole. Basis Disease. 2017;1863(4):917-928.
|
